Upgrade to SI Premium - Free Trial

Pacira Pharmaceuticals (PCRX) PT Raised to $62 at BMO Capital

November 5, 2021 6:49 AM
BMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $62.00 (from $60.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles